Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments head-to-head—proton beam therapy and intensity-modulated radiation therapy, or ...

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects. Patients with prostate cancer who receive ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up We investigated the SEER-Medicare linked database, identifying patients with ...

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors Men were randomly ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...